Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04954378
• Other study ID #: M2021060
• Status: Completed
• Start date: January 1, 2010
• Est. completion date: December 30, 2020

Study information

• Verified date: June 2021
• Source: Peking University Third Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis

Description:

Pancreatic cancer is the most malignant tumor of the digestive system and the seventh leading cause of cancer-related death worldwide.The rate of lymph node metastasis in pancreatic cancer is as high as 59%.Lymph node metastasis is an important prognostic factor, which is closely associated with poor prognosis of pancreatic cancer patients.Preoperative accurate prediction of lymph node status has important clinical value.At present, the preoperative LN status of pancreatic cancer patients is mainly evaluated by conventional imaging methods such as CT and MRI.The accuracy of evaluating LN state only from the perspective of morphology is poor.Ductal adenocarcinoma of the pancreas is highly malignant, has a median disease-free survival of only about 1 year, and most pancreatic cancer patients eventually relapse.At present, TNM staging system is mainly used for prognosis evaluation.However, even among patients with the same TNM stage, the prognosis is still significantly different, which reflects the lack of prognostic information provided by the TNM stage.Imaging omics extracts a large number of quantitative features from medical images in a high-throughput manner to enable non-invasive analysis of intra-tumor heterogeneity.In this study, we planned to construct a prediction study of preoperative lymph node metastasis and prognosis of pancreatic cancer based on multimodal imaging, so as to provide a basis for clinical treatment decision and prognosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• radical resection was performed, and histopathologically confirmed pancreatic ductal adenocarcinoma and lymph node status;2) CT and/or MRI enhancement examinations were performed 2 weeks before surgery;3) Patients with complete clinical data

Exclusion Criteria:

• (1)Patients who received radiotherapy or chemotherapy before preoperative imaging examination;2) Poor image quality.

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma

Intervention

Diagnostic Test:
• radiomics

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	radiomics features	1409 radiomics features can be extracted from the images.	After sketching the ROI